Published in J Clin Invest on February 01, 1996
CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol (2004) 3.53
Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology (2008) 2.91
Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J Virol (2003) 2.60
Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology (2004) 2.54
Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol (2004) 2.27
Hepatitis C virus-induced cryoglobulinemia. Kidney Int (2009) 1.60
Nonrandom distribution of hepatitis C virus quasispecies in plasma and peripheral blood mononuclear cell subsets. J Virol (1999) 1.42
Compartmentalization of hepatitis C virus genotypes between plasma and peripheral blood mononuclear cells. J Virol (2005) 1.41
Lack of evidence for hepatitis G virus replication in the livers of patients coinfected with hepatitis C and G viruses. J Virol (1997) 1.26
Modeling HCV kinetics under therapy using PK and PD information. Expert Opin Drug Metab Toxicol (2009) 1.22
Molecular and bioinformatic evidence of hepatitis C virus evolution in brain. J Infect Dis (2008) 1.18
Sequence analysis of the hepatitis C virus genome recovered from serum, liver, and peripheral blood mononuclear cells of infected chimpanzees. J Virol (1997) 1.17
Persistent hepatitis C virus infections and hepatopathological manifestations in immune-competent humanized mice. Cell Res (2014) 1.13
Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J Virol (2003) 1.13
Hepatitis C virus inhibits cell surface expression of HLA-DR, prevents dendritic cell maturation, and induces interleukin-10 production. J Virol (2008) 1.11
Expression of microRNA miR-122 facilitates an efficient replication in nonhepatic cells upon infection with hepatitis C virus. J Virol (2012) 1.10
Prospective comparison of whole-blood- and plasma-based hepatitis C virus RNA detection systems: improved detection using whole blood as the source of viral RNA. J Clin Microbiol (1999) 1.09
HCV replication in PBMC and its influence on interferon therapy. World J Gastroenterol (2003) 1.08
Cryoglobulinaemia and rheumatic manifestations in patients with hepatitis C virus infection. Ann Rheum Dis (1998) 1.06
Hepatitis C virus core protein leads to immune suppression and liver damage in a transgenic murine model. J Virol (2002) 1.05
Compartmentalization of hepatitis C virus quasispecies in blood mononuclear cells of patients with mixed cryoglobulinemic syndrome. J Virol (2005) 0.99
Human cell types important for hepatitis C virus replication in vivo and in vitro: old assertions and current evidence. Virol J (2011) 0.97
Hepatitis C virus productive infection in mononuclear cells from patients with cryoglobulinaemia. Clin Exp Immunol (2007) 0.96
Compartmentalization of hepatitis C virus (HCV) during HCV/HIV coinfection. J Infect Dis (2007) 0.95
Distribution of different hepatitis C virus genotypes in patients with hepatitis C virus infection. World J Gastroenterol (2010) 0.95
Flow cytometric detection of hepatitis C virus antigens in infected peripheral blood leukocytes: binding and entry. World J Gastroenterol (2005) 0.95
HCV-RNA positivity in peripheral blood mononuclear cells of patients with chronic HCV infection: does it really mean viral replication? World J Gastroenterol (2001) 0.95
Dendritic cells in hepatitis C infection: can they (help) win the battle? J Gastroenterol (2011) 0.94
Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naïve patients coinfected with human immunodeficiency virus and hepatitis C virus. Eur J Clin Microbiol Infect Dis (2003) 0.93
Hepatitis C virus infection of human T lymphocytes is mediated by CD5. J Virol (2012) 0.91
Viral RNA but no evidence of replication can be detected in the peripheral blood mononuclear cells of hepatitis E virus-infected patients. J Viral Hepat (2010) 0.87
Expression of type I interferon receptor in liver and peripheral blood mononuclear cells in chronic hepatitis C patients. Dig Dis Sci (2002) 0.86
Hepatitis C virus core protein induces an anergic state characterized by decreased interleukin-2 production and perturbation of mitogen-activated protein kinase responses. J Virol (2005) 0.85
Impact of hepatitis C virus coinfection on immune restoration during successful antiretroviral therapy in chronic human immunodeficiency virus type 1 disease. Eur J Clin Microbiol Infect Dis (2008) 0.83
Effects of HCV on basal and tat-induced HIV LTR activation. PLoS One (2013) 0.81
Molecular and contextual markers of hepatitis C virus and drug abuse. Mol Diagn Ther (2009) 0.80
Simultaneous evaluation of lymphocyte subpopulations in the liver and in peripheral blood mononuclear cells of HCV-infected patients: relationship with histological lesions. Clin Exp Immunol (2002) 0.80
Role of the exogenous HCV core protein in the interaction of human hepatocyte proliferation and macrophage sub-populations. PLoS One (2014) 0.80
Conserved Motifs within Hepatitis C Virus Envelope (E2) RNA and Protein Independently Inhibit T Cell Activation. PLoS Pathog (2015) 0.79
Hepatitis C virus and non-Hodgkin's lymphomas: Meta-analysis of epidemiology data and therapy options. World J Hepatol (2016) 0.76
Specialization of Hepatitis C Virus Envelope Glycoproteins for B Lymphocytes in Chronically Infected Patients. J Virol (2015) 0.76
Effect of in vitro interferon-beta administration on hepatitis C virus in peripheral blood mononuclear cells as a predictive marker of clinical response to interferon treatment for chronic hepatitis C. World J Gastroenterol (2004) 0.76
Inhibitory effect of miR-125b on hepatitis C virus core protein-induced TLR2/MyD88 signaling in THP-1 cells. World J Gastroenterol (2016) 0.75
It Is Imperative to Establish a Pellucid Definition of Chimeric RNA and to Clear Up a Lot of Confusion in the Relevant Research. Int J Mol Sci (2017) 0.75
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science (1989) 37.89
Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups. Proc Natl Acad Sci U S A (1990) 8.92
Detection of hepatitis C viral sequences in non-A, non-B hepatitis. Lancet (1990) 8.56
Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med (1989) 8.10
Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol (1993) 8.07
Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis (1995) 5.53
Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: comparison with reported isolates for conserved and divergent regions. J Gen Virol (1991) 5.03
Secondary structure of the 5' nontranslated regions of hepatitis C virus and pestivirus genomic RNAs. Nucleic Acids Res (1992) 4.58
Sequence analysis of the 5' noncoding region of hepatitis C virus. Proc Natl Acad Sci U S A (1992) 3.72
HCV-associated liver cancer without cirrhosis. Lancet (1995) 3.23
Hepatitis C virus infection in Egyptian volunteer blood donors in Riyadh. Lancet (1991) 2.96
Demonstration of in vitro infection of chimpanzee hepatocytes with hepatitis C virus using strand-specific RT/PCR. Virology (1994) 2.33
Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology (1992) 2.31
A novel transcription property of SP6 and T7 RNA polymerases: dependence on template structure. Nucleic Acids Res (1985) 2.25
Hepatitis C viral RNA in serum of patients with chronic non-A, non-B hepatitis: detection by the polymerase chain reaction using multiple primer sets. Hepatology (1991) 1.82
Detection of replicative intermediates of hepatitis C viral RNA in liver and serum of patients with chronic hepatitis C. J Clin Invest (1991) 1.77
Detection of the minus strand of hepatitis C virus RNA by reverse transcription and polymerase chain reaction: implications for hepatitis C virus replication in infected tissue. Hepatology (1992) 1.77
Peripheral blood leukocytes serve as a possible extrahepatic site for hepatitis C virus replication. J Gen Virol (1993) 1.73
HCV genotypes in chronic hepatitis C and response to interferon. Lancet (1992) 1.67
Specific detection of positive and negative stranded hepatitis C viral RNA using chemical RNA modification. Arch Virol (1994) 1.52
Detection of replicative form of hepatitis C virus RNA in peripheral blood mononuclear cells. J Infect Dis (1992) 1.49
Detection of hepatitis C virus ribonucleic acid in the serum by amplification with polymerase chain reaction. J Clin Invest (1990) 1.26
Use of conserved sequences from hepatitis C virus for the detection of viral RNA in infected sera by polymerase chain reaction. Hepatology (1991) 1.23
False detection of negative-strand hepatitis C virus RNA. Lancet (1994) 1.18
The physical state of the negative strand of hepatitis C virus RNA in serum of patients with chronic hepatitis C. Proc Natl Acad Sci U S A (1994) 1.08
Hepatitis C virus-RNAs in plasma and in peripheral blood mononuclear cells of hemophiliacs with chronic hepatitis C: evidence for viral replication in peripheral blood mononuclear cells. J Med Virol (1994) 1.05
Testing for hepatitis C virus sequences in peripheral blood mononuclear cells of patients with chronic hepatitis C in the absence of serum hepatitis C virus RNA. Liver (1994) 1.02
Hepatitis C virus RNA in plasma and blood mononuclear cells in patients with chronic hepatitis C treated with alpha-interferon. J Med Virol (1995) 0.97
Hepatitis C virus replication during acute infection in the chimpanzee. J Infect Dis (1992) 0.96
Specific detection of minus strand hepatitis A virus RNA by Tail-PCR following reverse transcription. Nucleic Acids Res (1994) 0.81
Single-step nested polymerase chain reaction for detection of different genotypes of hepatitis C virus. J Med Virol (1995) 0.80
Peripheral mononuclear cells of haemophiliacs with chronic liver disease are infected with replicating hepatitis C virus. Br J Haematol (1994) 0.79
Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol (1997) 5.00
Almost the entire 5' non-translated region of hepatitis C virus is required for cap-independent translation. FEBS Lett (1995) 2.72
Transcription of woodchuck hepatitis virus in the chronically infected liver. EMBO J (1985) 2.49
Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology (2001) 2.49
Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med (1985) 2.29
Immunity in hepatitis C infection. J Infect Dis (1992) 2.28
Sensitivity of serological assays to identify blood donors with hepatitis C viraemia. Lancet (1992) 2.25
Need for vaccination of sewer workers against leptospirosis and hepatitis A. Occup Environ Med (1995) 2.02
In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood (1998) 1.98
High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. J Hepatol (2001) 1.94
NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention. Ann Intern Med (1988) 1.88
Active hepatitis B virus replication in the presence of anti-HBe is associated with viral variants containing an inactive pre-C region. Virology (1990) 1.84
A genomic approach of the hepatitis C virus generates a protein interaction map. Gene (2000) 1.72
Hepatitis B virus genotype A rarely circulates as an HBe-minus mutant: possible contribution of a single nucleotide in the precore region. J Virol (1993) 1.71
Acute normovolemic hemodilution combined with hypotensive anesthesia and other techniques to avoid homologous transfusion in spinal fusion surgery. Spine (Phila Pa 1976) (1992) 1.69
Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol (2000) 1.59
Activation of c-myc by woodchuck hepatitis virus insertion in hepatocellular carcinoma. Cell (1988) 1.58
Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology (2000) 1.56
Seroepidemiologic study of three zoonoses (leptospirosis, Q fever, and tularemia) among trappers in Québec, Canada. Clin Diagn Lab Immunol (1995) 1.55
Replication capacities of natural and artificial precore stop codon mutants of hepatitis B virus: relevance of pregenome encapsidation signal. Virology (1992) 1.47
Clinical impact of occult HBV infections. J Clin Virol (2005) 1.46
Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion. J Exp Med (1991) 1.44
Epidemiology, demographics, and genetics of sarcoidosis. Semin Respir Infect (1998) 1.42
Predictions of liver histology from laboratory tests and demographic data [corrected]. Lancet (1998) 1.39
Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties. Virology (1998) 1.37
In vitro replication competence of a cloned hepatitis B virus variant with a nonsense mutation in the distal pre-C region. Virology (1991) 1.36
Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore) (1995) 1.35
Rearrangement and enhanced expression of c-myc in hepatocellular carcinoma of hepatitis virus infected woodchucks. Nature (1987) 1.25
Duck hepatitis B virus can tolerate insertion, deletion, and partial frameshift mutation in the distal pre-S region. J Virol (1989) 1.23
Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. J Natl Cancer Inst (2000) 1.23
Identification of an immunodominant epitope within the capsid protein of hepatitis C virus. Proc Natl Acad Sci U S A (1991) 1.18
Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research. Eur J Gastroenterol Hepatol (2000) 1.16
Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology (1999) 1.15
Leptospirosis in raccoons in Quebec: 2 case reports and seroprevalence in a recreational area. Can Vet J (1997) 1.14
Dynamic analysis of hepatitis C virus replication and quasispecies selection in long-term cultures of adult human hepatocytes infected in vitro. J Gen Virol (1999) 1.13
A twelve year natural history of hepatitis C virus infection in hemodialyzed patients. Kidney Int (1994) 1.11
The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference. J Viral Hepat (2013) 1.10
Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. J Virol (2004) 1.09
Proofs of the structure of lipid coated nanoparticles (SMBV) used as drug carriers. Pharm Res (2000) 1.09
Heterogeneity of familial risk in sarcoidosis. Genet Epidemiol (1996) 1.06
Activation of Ki-ras gene by point mutation in human liver angiosarcoma associated with vinyl chloride exposure. Mol Carcinog (1991) 1.04
DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J Virol (1995) 1.03
Rapid detection and further characterization of infection with hepatitis B virus variants containing a stop codon in the distal pre-C region. J Gen Virol (1990) 1.03
Current management strategies for hepatitis B in the elderly. Drugs Aging (2001) 1.03
Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. J Med Virol (1996) 1.03
Angiotensin-converting enzyme gene polymorphism and risk of sarcoidosis. Am J Respir Crit Care Med (1998) 1.02
An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses. Vaccine (2007) 1.02
Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites. J Virol (2001) 1.02
Removal of cell-bound lipoproteins: a crucial step for the efficient infection of liver cells with hepatitis C virus in vitro. C R Acad Sci III (2001) 1.01
Effects of 2'-fluorinated arabinosyl-pyrimidine nucleosides on duck hepatitis B virus DNA level in serum and liver of chronically infected ducks. J Med Virol (1992) 1.00
Two French genotypes of hepatitis C virus: homology of the predominant genotype with the prototype American strain. Gene (1991) 1.00
Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B. J Infect Dis (2000) 0.99
Residues critical for duck hepatitis B virus neutralization are involved in host cell interaction. J Virol (1999) 0.99
HCV core immunodominant region analysis using mouse monoclonal antibodies and human sera: characterization of major epitopes useful for antigen detection. J Med Virol (1998) 0.99
Virus-neutralizing monoclonal antibody to a conserved epitope on the duck hepatitis B virus pre-S protein. J Virol (1990) 0.98
Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C. J Med Virol (2007) 0.97
Use of a TT virus ORF1 recombinant protein to detect anti-TT virus antibodies in human sera. J Gen Virol (2000) 0.97
Inhibitory effect of 2'-fluoro-5-methyl-beta-L-arabinofuranosyl-uracil on duck hepatitis B virus replication. Antimicrob Agents Chemother (1998) 0.95
Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination. DNA Cell Biol (1999) 0.95
Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy. J Viral Hepat (2004) 0.95
2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. Antimicrob Agents Chemother (1996) 0.95
Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J Hepatol (1998) 0.94
Natural cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) is not impaired in patients suffering from chronic hepatitis C. J Hepatol (2001) 0.94
Early stages of rabbit haemorrhagic disease virus infection monitored by polymerase chain reaction. Zentralbl Veterinarmed B (1996) 0.93
Comparison of HCV RNA assays for the detection and quantification of hepatitis C virus RNA levels in serum of patients with chronic hepatitis C treated with interferon. J Med Virol (1997) 0.92
Heterogeneity of hepatitis C virus genotypes in France. J Gen Virol (1994) 0.92
Early and frequent detection of HBxAg and/or anti-HBx in hepatitis B virus infection. Hepatology (1990) 0.92
In vitro and in vivo replication capacity of the precore region defective hepatitis B virus variants. J Hepatol (1991) 0.92
Clinical evaluation of the branched DNA assay for hepatitis B virus DNA detection in patients with chronic hepatitis B lacking hepatitis B e antigen and treated with interferon-alpha. J Viral Hepat (1998) 0.91
Investigations into the cross-reactivity of rabbit antibodies raised against nonhomologous pairs of synthetic peptides derived from HIV-1 gp120 proteins. J Pept Res (1998) 0.91
Genetics of sarcoidosis. Clin Chest Med (1997) 0.91
Interferon-alpha 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation. Hepatology (1993) 0.90
Therapeutic activity of vidarabine in symptomatic chronic active hepatitis related to HBV. J Hepatol (1986) 0.90
Familial risk ratio of sarcoidosis in African-American sibs and parents. Am J Epidemiol (2001) 0.90
Hepatitis C virus genotypes in France: comparison of clinical features of patients infected with HCV type I and type II. J Hepatol (1994) 0.90
Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. J Viral Hepat (1998) 0.90
Role of silent hepatitis B virus in chronic hepatitis B surface antigen(-) liver disease. Antiviral Res (2001) 0.89
Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization. J Virol (1999) 0.89
Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo. J Hepatol (2001) 0.89
The hepatitis B virus and the peripheral blood mononuclear cells: a brief review. J Hepatol (1990) 0.89
Long-term results of liver transplantation for Wilson's disease. Gastroenterol Clin Biol (2008) 0.88
Recent dramatic decrease in AIDS cases and HIV-related deaths contrasts with stable rate of new HIV-positive patients detected in Lyon, France, from 1988 to 1997. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 0.88
n-Butyrate, a cell cycle blocker, inhibits early amplification of duck hepatitis B virus covalently closed circular DNA after in vitro infection of duck hepatocytes. J Virol (1996) 0.88